Zenas BioPharma, Inc.

XNASHealth care

Last traded price · USD

$28.46

+0.28%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:26 IST · A quote does not mean the product is available to trade on your account.

Day's open: $29.27
Previous close: $28.38
Volume: 800,741
Day's high: $29.91
Day's low: $28.01

In brief

Zenas BioPharma, Inc. is a health care company listed on Nasdaq, valued at about $1.85B.
Its shares closed at $28.46 on 4 Nov 2026, down 5.0% over the past year.
From India you can buy ZBIO in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Zenas BioPharma, Inc. (ZBIO) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ZBIO share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ZBIO options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

18.8 days to cover short interest
12.5M shares were sold short at the 15 Oct 2026 settlement, 19.2% of the 65.2M shares outstanding; covering them would take 18.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Behind SPY and its sector fund XLV over 1 year
1 month: +5.6% (SPY −1.6%, XLV +13.5%). 3 months: −10.7% (SPY −0.4%, XLV +15.5%). 1 year: −5.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ZBIO, SPY and XLV · as of 4 Nov 2026
Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $28.46 was 2.6% below its 50-day average ($29.21) and 13.5% above its 200-day average ($25.07). It has closed above the 200-day for 92 sessions, since 26 Jun 2026. The 50-day average crossed above the 200-day on 11 Aug 2026, 60 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
48% of the way up its 52-week range
Closed at $28.46 on 4 Nov 2026: 36.2% below the 52-week high of $44.60 (24 Dec 2025) and 110.8% above the low of $13.50 (5 Jan 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+5.6%

6 months+36.6%

1 year−5.0%

5 years—

Newswire

About

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.

Website

Notable moves

January 5, 2026
−51.86%
October 27, 2025
+33.08%
October 8, 2025
+24.22%

Zenas BioPharma, Inc.

XNASHealth care

Last traded price · USD

$28.46

+0.28%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:26 IST · A quote does not mean the product is available to trade on your account.

Day's open: $29.27
Previous close: $28.38
Volume: 800,741
Day's high: $29.91
Day's low: $28.01

In brief

Zenas BioPharma, Inc. is a health care company listed on Nasdaq, valued at about $1.85B.
Its shares closed at $28.46 on 4 Nov 2026, down 5.0% over the past year.
From India you can buy ZBIO in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Zenas BioPharma, Inc. (ZBIO) shares from India?

Do I need the price of a whole ZBIO share to invest?

How much can I invest in US stocks in a year?

Can I trade ZBIO options or futures?

Insights

Quotes run fifteen minutes behind.

18.8 days to cover short interest
12.5M shares were sold short at the 15 Oct 2026 settlement, 19.2% of the 65.2M shares outstanding; covering them would take 18.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Behind SPY and its sector fund XLV over 1 year
1 month: +5.6% (SPY −1.6%, XLV +13.5%). 3 months: −10.7% (SPY −0.4%, XLV +15.5%). 1 year: −5.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ZBIO, SPY and XLV · as of 4 Nov 2026
Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $28.46 was 2.6% below its 50-day average ($29.21) and 13.5% above its 200-day average ($25.07). It has closed above the 200-day for 92 sessions, since 26 Jun 2026. The 50-day average crossed above the 200-day on 11 Aug 2026, 60 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
48% of the way up its 52-week range
Closed at $28.46 on 4 Nov 2026: 36.2% below the 52-week high of $44.60 (24 Dec 2025) and 110.8% above the low of $13.50 (5 Jan 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+5.6%

6 months+36.6%

1 year−5.0%

5 years—

Newswire

About

Website

Notable moves

January 5, 2026
−51.86%
October 27, 2025
+33.08%
October 8, 2025
+24.22%

Zenas BioPharma, Inc.

Zenas BioPharma, Inc. in brief

18.8 days to cover short interest

Behind SPY and its sector fund XLV over 1 year

Below its 50-day average, above its 200-day

48% of the way up its 52-week range

Zenas BioPharma, Inc.

Zenas BioPharma, Inc. in brief

18.8 days to cover short interest

Behind SPY and its sector fund XLV over 1 year

Below its 50-day average, above its 200-day

48% of the way up its 52-week range